Full-Time

Executive Director Internal Fill/Finish Manufacturing

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$236.1k - $393.5k/yr

Expert

Albany, NY, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Regeneron Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree in any of the physical or biological sciences or engineering field
  • 15+ years of biopharmaceutical/biotech experience in a GMP drug product production facility
  • 5 years of experience reporting to or interacting closely with Senior Leadership
  • Expert knowledge of parenteral manufacturing, including finished doses for both clinical and commercial medicines
  • Highly experienced in leading all aspects of manufacturing operations in an aseptic biologics manufacturing environment
  • Solid understanding of production planning, scheduling, and leveling
  • Deep understanding of aseptic processes, equipment, automation, validation and cleanrooms and other classified area requirements
  • Proven track record of leading a site leadership team with cross-functional members as well as direct reports
  • Ability to think strategically and solve sophisticated challenges while being able to quickly adapt to emerging situations
Responsibilities
  • Provides executive level leadership, vision and management to the Fill/Finish site
  • Leads all aspects of Fill/Finish Operations at the facility to manufacture commercial and clinical parenteral medicines according to approved protocols, regulations and schedules
  • Guides and influences validation activities involving equipment and processes
  • Partners with Project Management to implement new production processes, including but not limited to formulation, filling, lyophilization, PFS and auto injector assemblies and finished product label and carton
  • Leads key manufacturing metrics/site goals, supports critical program milestones and drives continuous improvement initiatives that are essential to meeting patient and business needs
  • Leads all aspects of production planning and builds production schedules based on supply chain demand forecasts and resource availability
  • Manages relationships with external departments to schedule activities such as maintenance, cleaning, validation, microbial monitoring, etc.
  • Tracks start and end times of unit operations to monitor schedule attainment
  • Owns resource and capacity planning initiatives and works to seek improvement of systems and tools
  • Collaborates with Human Resources and other functions to develop a multi-year staffing and recruiting plan for the facility
  • Quickly and accurately communicates issues to Senior Leadership
  • Resolves manufacturing and facility issues to mitigate any supply disruptions to our patients
  • Works effectively across IOPS departments, such as Quality Assurance, Facilities, Engineering, External Manufacturing, MSAT, Regulatory, Quality Control, IT and Supply Chain
  • Writes, reviews and/or approves Standard Operating Procedures, specifications, regulatory filing or other controlled documents as needed
  • Ensures the effective use of material, equipment and personnel in producing quality products
  • Ensures that IOPS safety standards are maintained
  • Prepares and coordinates expense and capital budgets for the facility
  • Recommends capital expenditures and aids in the realization of capital projects
  • Oversees, supports and participates in cGMP audits of all production areas within the facility
  • Maintains site inspection readiness and represents the manufacturing facility during regulatory and client audits
  • Provides technical input to resolve manufacturing process challenges
Desired Qualifications
  • Experience with multiproduct biologics facility start-up is preferred
  • Working knowledge of industry practices, global regulations and experience interacting with across multiple health authorities (e.g. FDA, EMA, PMDA, etc.)
  • Enjoy being challenged to think critically, embracing new technologies and has a passion for continuously improving processes and operations
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron generates revenue by selling its approved medicines and through licensing agreements, sharing costs and profits with partners in co-development projects. Unlike many competitors, Regeneron emphasizes strong research capabilities and strategic partnerships to stay ahead in the biotechnology field. The company's goal is to improve patient outcomes by delivering effective treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent's approval for CSU opens a new market segment in the US.
  • $3.6 billion Tarrytown expansion boosts research capabilities and local economy.
  • Partnership with Fujifilm enhances manufacturing capacity for biologics.

What critics are saying

  • Tarrytown expansion poses financial risk if ROI is not realized.
  • Dependency on Fujifilm for manufacturing may lead to operational risks.
  • Regulatory setbacks, like Dupixent's initial rejection, can impact market entry.

What makes Regeneron Pharmaceuticals unique

  • Regeneron specializes in life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug development.
  • Regeneron collaborates with academic and research institutions to enhance R&D efforts.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

Ophthalmology Times
Apr 28th, 2025
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR

Regeneron has announced the upcoming presentation of 27 abstracts, including 8 oral presentations on aflibercept injection 8 mg (EYLEA HD) in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.

Pharma Journalist
Apr 24th, 2025
Regeneron Invests in Expanding Biologic Medicine Manufacturing

Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities.

PharmiWeb
Apr 24th, 2025
Dupixent Approved In The Us As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks

Texas Border Business
Apr 23rd, 2025
America's Manufacturing Power Surges as Global Giants Invest Billions

Additionally, Regeneron is investing approximately $3.6 billion to expand its Tarrytown, New York facility, aiming to double its manufacturing capabilities nearly.

Pharmaceutical Technology
Apr 22nd, 2025
Regeneron partners with Fujifilm to broaden manufacturing capacity

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity.